You searched for: epoprostenol (Engelska - Slovenska)

combination with epoprostenol
kombinacija z epoprostenolom

as a drug, it is also known as "epoprostenol".
heinrich himmler je tako med leti 1934 in 1938 osebno pregledal vse prošnje.

at baseline in future 1, 9 patients were taking epoprostenol.
ob izhodišču je v študiji future 1 9 bolnikov jemalo epoprostenol.

revatio can be used with epoprostenol (another medicine used in pah).
zdravilo revatio se lahko uporablja z epoprostenolom (drugim zdravilom za bolezen pah).

combination with epoprostenol the combination of tracleer and epoprostenol has been investigated in two studies:
15 kombinacija z epoprostenolom kombinacijo zdravila tracleer in epoprostenola so raziskovali v dveh študijah:

the estimates may have been influenced by the initiation of epoprostenol treatment in 43/235 patients.
pri 43/235 bolnikih je na oceno morda vplivalo zdravljenje z epoprostenolom.

patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study.
bolniki, vključeni v študijo, v kateri so kot dodatno zdravljenje prejemali še epoprostenol, so bili primerni za dolgoročno odprto podaljšano študijo.

half of the patients in each group were already being treated with intravenous epoprostenol and the dose of epoprostenol remained constant for the duration of the study.
polovica bolnikov v vsaki skupini je že prejemala epoprostenol intravensko, odmerek epoprostenola je med trajanjem študije ostal nespremenjen.

co-administration of sildenafil and intravenous epoprostenol has been evaluated (see section 4.8 and 5.1).
raziskana je bila sočasna uporaba sildenafila in intravenskega epoprostenola (glejte poglavji 4. 8 in 5. 1).

co-administration of oral sildenafil and intravenous epoprostenol has been evaluated (see sections 4.8 and 5.1).
ocenjena je bila sočasna uporaba peroralnega sildenafila in intravenskega epoprostenola (glejte poglavji 4.8 in 5.1).

therapy that is recommended at the severe stage of the disease (e.g. epoprostenol) should be considered if the clinical condition deteriorates.
Če se klinično stanje poslabša, je treba razmisliti o obliki zdravljenja, ki je priporočljiva za hud stadij bolezni (npr. epoprostenol).

revatio was more effective than placebo when it was added to epoprostenol, with walking distances increasing by 30.1 and 4.1 metres, respectively, after 16 weeks of treatment.
zdravilo revatio, dodano epoprostenolu, je bilo učinkovitejše od placeba, saj se je prehojena razdalja po 16 tednih zdravljenja povečala za 30, 1 metra v primerjavi s 4, 1 metra, doseženih s placebom.

patients were randomised to placebo or sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day) when used in combination with intravenous epoprostenol.
bolnike so randomizirali na placebo ali sildenafil (v fiksni titraciji najprej 20 mg, nato 40 mg in 80 mg trikrat na dan), uporabljen v kombinaciji z intravenskim epoprostenolom.

the known adverse events headache, flushing, pain in extremity and oedema were noted in a higher frequency in sildenafil/epoprostenol treated patients compared to placebo/epoprostenol treated patients.
znani neželeni učinki glavobol, zardevanje, bolečine v udih in edemi so bili pogostejši pri bolnikih, ki so dobivali sildenafil/epoprostenol, kot pri tistih, ki so dobivali placebo/epoprostenol.

transfer to a therapy that is recommended at the severe stage of the disease (e.g., epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).
Če pride do poslabšanja kliničnega stanja (glejte poglavje 4.2), premislite o prevedbi na zdravljenje, priporočeno za hudo obliko bolezni (denimo, epoprostenol).